TSX News -
Media Advisory: Hut 8 to Release Q1 2024 Results May 15
Miami, Fla, April 24, 2024 (GLOBE NEWSWIRE) — Hut 8 Corp. (Nasdaq | TSX: HUT) (“Hut 8” or the “Company”), […]
Kraken Robotics Appoints Peter Hunter as Chairman of Board of Directors
ST. JOHN’S, Newfoundland and Labrador, April 24, 2024 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (“Kraken” or the “Company”) (TSX-V: PNG, […]
LNG Energy Group Announces Signing of Hydrocarbon Productive Participation Contracts in Venezuela
Highlights: LNG Energy Group has been conditionally awarded two Productive Participation Contracts (“CPPs”) to develop and produce hydrocarbons in Venezuela. […]
Standard Lithium Successfully Commissions First Commercial-Scale DLE Column in North America
EL DORADO, Ark., April 24, 2024 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) […]
Constellium Reports First Quarter 2024 Results
PARIS, April 24, 2024 (GLOBE NEWSWIRE) — Constellium SE (NYSE: CSTM) (“Constellium” or the “Company”) today reported results for the […]
Comstock Completes RenFuel Investment
VIRGINIA CITY, Nev., April 24, 2024 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced the […]
Grab to Announce First Quarter 2024 Results on May 15, 2024
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) — Grab Holdings Limited (NASDAQ: GRAB, the “Company” or “Grab”), plans to announce […]
HighPeak Energy, Inc. Announces 2024 First Quarter Earnings Release and Conference Call Dates
FORT WORTH, Texas, April 24, 2024 (GLOBE NEWSWIRE) — HighPeak Energy, Inc. (NASDAQ: HPK) (“HighPeak Energy”), today announced that it […]
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with […]
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary […]
